Jingwen Yang , Yuan Ma , Ran Zhang , Xiangyi Liu , Wenjing Liu , Chen Liu , Jiangan Guan , Wenwen Chen , Jie Weng , Mengying Xie , Zhibin Wang , Xinlong Wan , Zhiyi Wang , Chan Chen
{"title":"Fibrotic extracellular matrix microenvironment induces alveolar type II epithelial cell senescence via integrin-β1/FAK/YAP signaling pathway","authors":"Jingwen Yang , Yuan Ma , Ran Zhang , Xiangyi Liu , Wenjing Liu , Chen Liu , Jiangan Guan , Wenwen Chen , Jie Weng , Mengying Xie , Zhibin Wang , Xinlong Wan , Zhiyi Wang , Chan Chen","doi":"10.1016/j.intimp.2025.115169","DOIUrl":null,"url":null,"abstract":"<div><div>Senescent alveolar epithelial cells (AEC) play a pivotal role in the progression of idiopathic pulmonary fibrosis (IPF), attracting increasing attention from researchers. Central to the pathogenesis of pulmonary fibrosis (PF) is the excessive deposition of extracellular matrix (ECM). However, there remains a significant gap in understanding how the ECM microenvironment influences senescence in type II alveolar epithelial cells (AEC II). This study investigates the activation of the integrin-β<sub>1</sub>/FAK/YAP signaling pathway and its role in inducing cellular senescence in both in vivo and in vitro models of bleomycin (BLM)-induced PF. We employed decellularized lung scaffolds (DLS) to replicate the natural ECM microenvironment, aiming to elucidate whether the fibrotic ECM promotes AEC II senescence through the integrin-β<sub>1</sub>/FAK/YAP pathway. Notably, our findings indicate that exogenous integrin-β<sub>1</sub> does not induce AEC II senescence. This suggests that the fibrotic ECM microenvironment regulates AEC II senescence via the integrin-β<sub>1</sub>/FAK/YAP pathway independently of exogenous integrin-β<sub>1</sub>. Therefore, targeting alterations in the fibrotic ECM microenvironment may represent a promising therapeutic strategy for IPF by modulating AEC II senescence.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"162 ","pages":"Article 115169"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925011592","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Senescent alveolar epithelial cells (AEC) play a pivotal role in the progression of idiopathic pulmonary fibrosis (IPF), attracting increasing attention from researchers. Central to the pathogenesis of pulmonary fibrosis (PF) is the excessive deposition of extracellular matrix (ECM). However, there remains a significant gap in understanding how the ECM microenvironment influences senescence in type II alveolar epithelial cells (AEC II). This study investigates the activation of the integrin-β1/FAK/YAP signaling pathway and its role in inducing cellular senescence in both in vivo and in vitro models of bleomycin (BLM)-induced PF. We employed decellularized lung scaffolds (DLS) to replicate the natural ECM microenvironment, aiming to elucidate whether the fibrotic ECM promotes AEC II senescence through the integrin-β1/FAK/YAP pathway. Notably, our findings indicate that exogenous integrin-β1 does not induce AEC II senescence. This suggests that the fibrotic ECM microenvironment regulates AEC II senescence via the integrin-β1/FAK/YAP pathway independently of exogenous integrin-β1. Therefore, targeting alterations in the fibrotic ECM microenvironment may represent a promising therapeutic strategy for IPF by modulating AEC II senescence.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.